STOCK TITAN

BioStem Technologies: Matuszewski reports 17.4% stake

Certain restricted stock units and options covering 497,411 and 440,529 shares, respectively, were not scheduled to vest on or before November 29, 2026.

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

BioStem Technologies, Inc. (BSEM) reported that Jason Matuszewski beneficially owned 3,665,899 shares of Common Stock, or 17.4% of the class, as of September 30, 2026. The total includes 1,303,551 shares held directly, 2,250,000 shares issuable under fully vested options with a $2.00 exercise price, and additional shares issuable under other options and convertible preferred stock.

The percentage calculation uses 18,672,125 shares outstanding as of October 1, 2026, plus 2,362,348 shares issuable to him within 60 days of September 30, 2026. The reported ownership excludes restricted stock units covering 497,411 shares and options for 440,529 shares, neither scheduled to vest on or before November 29, 2026.

Beneficial ownership 3,665,899 shares As of September 30, 2026
Percent of class 17.4% Beneficial ownership reported as of September 30, 2026
Shares held directly 1,303,551 shares Included in beneficial ownership
Fully vested options 2,250,000 shares at $2.00 per share Options expire October 24, 2032
Shares issuable under vested options 98,907 shares at $10.05 per share Vested portion of options to purchase 198,807 shares; expire March 17, 2035
Shares issuable under options vesting 13,341 shares at $10.05 per share Vests October 13, 2026; part of options to purchase 40,427 shares
Shares issuable within 60 days 2,362,348 shares Included in the percentage calculation; measured from September 30, 2026
Shares outstanding 18,672,125 shares As of October 1, 2026
beneficially owned financial
"Amount beneficially owned: 3,665,899 shares of Common Stock"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Voting Power financial
"Sole Voting Power 3,665,899.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 3,665,899.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
restricted stock units financial
"restricted stock units covering an aggregate of 497,411 shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Series A-1 Convertible Preferred Shares financial
"conversion of 100 Series A-1 Convertible Preferred Shares"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BSEM shares does Jason Matuszewski beneficially own?

Jason Matuszewski reported beneficial ownership of 3,665,899 shares, equal to 17.4% of BioStem's Common Stock. The calculation used 18,672,125 shares outstanding as of October 1, 2026, plus 2,362,348 shares issuable to him within 60 days of September 30, 2026.

What securities are included in Jason Matuszewski's BSEM ownership?

The total includes 1,303,551 shares held directly; 2,250,000 shares issuable under fully vested options at $2.00 per share, expiring October 24, 2032; 98,907 shares from vested options and 13,341 shares from options vesting October 13, 2026, each at $10.05 per share; and 100 shares issuable on conversion of 100 Series A-1 Convertible Preferred Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





090684200

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: (1) Based on 18,672,125 shares of Common Stock outstanding as of October 1, 2026, as reported in the Issuer's Registration Statement on Form S-1 filed on October 2, 2026, plus 2,362,348 shares issuable to the Reporting Person upon exercise or conversion of derivative securities exercisable within 60 days of September 30, 2026, computed in accordance with Rule 13d-3(d)(1)(i).


SCHEDULE 13G



Jason Matuszewski
Signature:/s/ Jason Matuszewski
Name/Title:Jason Matuszewski
Date:11/10/2026

Keep reading